CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to B-cell Lymphoma
Related studies linked through entity extraction aliases.
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- Status
- RECRUITING
- Phase
- PHASE2
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
- Status
- RECRUITING
- Phase
- N/A
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2